

### **Corporate Presentation**

October 2022

# Healthcare in Africa

23% of Global Disease Burden, Disproportionate Share



### Population

**16% of the global population**; 60% of African population live in rural isolated areas, 83% excluded from healthcare services



#### Infrastructure

**1% global healthcare expenditure**; 0.3 physician, 1.0 nurse, 1.3 hospital beds per 1,000 people



#### Affordability

High costs of biologic treatments combined with out-of-pockets payments limiting access




#### Diagnosis

Low, resulting in **poor outcome**; in cancer, as many as 80% of patients diagnosed late/end stage



# Minapharm Group Journey in Biopharma Started 20+ Years Ago





# MiGenTra, Healthcare Transforming Medicines for Africa

Incorporated April 2021 by ProBioGen AG and MinaPharm Pharmaceuticals



ProBio*G*en

#### Intelligent Biopharmaceutical Solutions

Internationally known partner with 20 years experiences in biopharmaceutical cell development, manufacturing & analytic of complex therapeutic proteins. *Berlin, Germany; 250+ employees* 



Dedicated to the end-to-end development and commercialization of high quality affordable biologic medicines in the field of Biosimilars, Celland Gene Therapies and Vaccines to serve the needs of patients across Africa and the Middle East, a unique constellation hard to be replicated in the foreseeable future. Berlin, Germany

# MINAPHARM S

Only gene-to-market biopharmaceutical company in Africa & the Middle East region with 20 years of track record in biotech and local end-to-end manufacturing site in Egypt, GMP compliant. *Cairo, Egypt; 1,500+ employees* 





# **Organizational Chart**

Executive Team



**Dr. Lutz Hilbrich** Chief Executive Officer, MiGenTra GmbH & ProBioGen AG



**Dr. Shaheer Bardissi** Executive Board Member, Minapharm Pharmaceuticals



Frédéric Bouvier Head Corporate Development & Business Development & Licencing, MiGenTra GmbH



Andrea Hauptmann Chief Financial Officer, MiGenTra GmbH & ProBioGen AG

International External Advisors



Heidi Hunter, President Specialty Solutions Business at Cardinal Health, US



**Prof. Dr. Petra Reinke,** Professor of Medicine & founding director of the Berlin Center for Advanced Therapies (BeCAT), Germany



### Healthcare is a Human Right



Providing quality & affordable biological medicines to more patients across Africa & the Middle-East



**Transforming healthcare** in Africa & the Middle East



# Strategic Pillars: TREAT

Holistic Approach to Delivering on Our Ambition.

### THERAPIES

Bring an industry-leading portfolio of biologic therapies covering multiple modalities to market

### **REA**сн

Geographic expansion and telehealth solutions to serve the maximum number of patients

### TRANSFORMATION

Make innovation affordable by providing quality biologic therapies at affordable prices



# In-House Pipeline of Biosimilars

Track Record of Successful Biosimilar Developments

		Therapeuti	C					
Product	INN	Area		Cell-Line	Preclinical	Clinical	Filed	Marketed
Gonapure	rHu-FSH <sup>[1]</sup>	Infertility						• 2014 <sup>[3]</sup>
Reiferon Retard	r-IFN <sup>[2]</sup> alfa-2a	HCV						<b>2006</b> <sup>[3]</sup>
Thrombexx	r-hirudin	Thrombosis						• 2005 <sup>[3]</sup>
Bonosome <sup>[4]</sup>	<b>TERI</b> paratide	Osteoporosis	<b>~</b>				•	<b>2022</b> <sup>[5]</sup>
Adessia	<b>ADA</b> limumab	Autoimmune	Å					2024 <sup>[5]</sup>
MP-103	undisclosed	Oncology	- <b>*</b>		•			<b>2025</b> <sup>[5]</sup>
MP-104	undisclosed	Oncology	- <b>**</b> *		•			<b>2025</b> <sup>[5]</sup>
MGT-2201	undisclosed	Oncology	- <b>**</b> *	•				2026 [5]
MGT-2202	undisclosed	Oncology	- <b>**</b> *	•				<b>2027</b> <sup>[5]</sup>
MGT-2203	undisclosed	Oncology	- <b>**</b> *	•				2028 <sup>[5]</sup>
8 11-Jan-23	MiGenTra Corporate Presentation					<ol> <li>Follitropin alpha</li> <li>Interferon</li> <li>First launch, Egypt</li> <li>First Teriparatide dev phase I clinical trail perfo</li> <li>expected launch in Eg</li> </ol>		GenTra Heathcare Tanaforning Miccines

## Innovation Made Affordable Leveraging the Best of Two Worlds


Uniquely positioned to serve Africa with quality biologic therapies at affordable cost






# **Transforming Healthcare**

### Reiferon Retard Case Study






- Launched in 2006
- 6-fold reduction in price of the originator
- 115 folds increase in number of patients

Outcomes:

- Market expansion with greater number of patients having access to interferon treatments
- Market leadership of Minapharm's Reiferon Retard
- Acknowledgments from specialized press and authorities








# **Transforming Healthcare**

### Gonapure Case Study







- Launched Dec 2014
- 35% price reduction 50% increase in number of patients

#### Outcomes:

- Market expansion with greater number of patients having access to FSH treatments
- Market leadership of Minapharm's Gonapure







# New Cutting Edge Biomanufacturing Facility

Minapharm's 2<sup>nd</sup> Biofacility in Egypt; Unique in Africa & the Middle East

- 6 floors, **15,000m<sup>2</sup>** total floor space
- 1 floor fully equipped with automated single use bioreactors w/ total capacity of 11kL
- Fully integrated, from drug substance to fill & finish, quality control, storage of starting materials and intermediates
- GMP compliant\*





\* Certification via MHRA or LaGeSo ongoing

# **Commercial Ready Now**

Current Network and Planned Geographic Expansion to Cover Most of Africa & Middle-East.



Presence in **12 markets** via 18 partners; **active expansion ongoing** through new product registrations





# Providing quality & affordable biological medicines to more patients across Africa & the Middle-East

NUUCICI A